Exact Sciences Corporation

first quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed with the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Derek LaCalle, VP of Investor Relations. Please go ahead.

Thanks, operator. Thank you for joining us for Exact Sciences' first quarter 2025 conference call. On the call today are Kevin Conroy, the company's chairman and CEO, and Aaron Bloomer, our chief financial officer. Exact Sciences issued a news release earlier this afternoon detailing our first quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with exact sciences are included in our SEC filings. Both can be accessed through our website. I will now turn the call over to Kevin.

Thanks, Derek. Highlights in the first quarter include delivering 1.2 million total results to patients, Growing core revenue 11% while non-GAAP operating expenses grew just 4%. Improving our profitability by increasing adjusted EBITDA more than 60%. Launching Cologuard Plus, our next generation Cologuard test with Medicare coverage and quality measure inclusion and being recognized as a Gallup exceptional workplace for the second year in a row. Cologuard is driving significant and durable growth because it satisfies an unmet need in an expanding market. We're pleased to share some of the early successes from the commercial initiatives we began last year. Our purpose-built commercial organization and expanded field team are engaging providers with the highest potential to order at record rate. The shift to territories and calling on providers with the highest potential to order is making our team even more effective. Our team is expanding the number of providers we engage in each quarter. As a result, they are helping reach new ordering providers much faster. We're also seeing positive feedback from new advertising campaigns and customer satisfaction was at an all-time high in the first quarter. Our customer initiated ordering platform grew triple digits in the first quarter, and we have plans to improve these initiatives further. We're incredibly proud of our entire commercial organization and their positive impact on advancing our mission. Commercial improvements are just one of many drivers that will fuel growth over the coming years. Others include our rescreen program. We have a growing base of loyal customers, which now represent more than 25% of our revenue. This provides a predictable recurring source of revenue, and we are getting even better at keeping those patients screened. Our CareGap program. This program helps payers and health systems close gaps in screening. This program grew triple digits last year and will continue to grow strong double digits this year. We are still in the early innings of driving higher adherence in these programs. The launch of Cold Guard Plus. This will deliver increased value, improved performance, higher adoption, and improved margins. New products. We're starting to see the benefit of investments we've made to launch and scale new tests in large and growing markets. These growth drivers will continue to play out over 2025 and beyond. It's never been a more exciting time than that. I'll now pass it on to Aaron to discuss our first quarter financial results and provide an updated outlook for 2025.